PLB 1003

Drug Profile

PLB 1003

Alternative Names: PLB1003

Latest Information Update: 09 May 2017

Price : $50

At a glance

  • Originator Beijing Pearl Biotechnology
  • Class Antineoplastics
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 08 Nov 2016 Phase-I clinical trials in Non-small cell lung cancer in China (PO) (NCT03130881)
  • 29 Feb 2016 Beijing Pearl Biotechnology files an IND application with the CFDA in China for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top